NCT00083824View on ClinicalTrials.gov

Estrogen, HDL, and Coronary Heart Disease in Women

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Cardiovascular DiseasesCoronary DiseaseHeart DiseasesCoronary Arteriosclerosis
Interventions
DRUG

Estrogens, Conjugated (USP)

0.625 mg/day QID for 3 years

DRUG

Medroxyprogesterone 17-Acetate

2.5 mg/day QID for 3 years

DRUG

Placebo

2 pills/day QID for 3 years

Trial Locations (1)

02111

HNRCA at Tufts University, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Tufts University

OTHER

NCT00083824 - Estrogen, HDL, and Coronary Heart Disease in Women | Biotech Hunter | Biotech Hunter